This website collects cookies to deliver better user experience, you agree to the Privacy Policy.
Accept
Sign In
The Texas Reporter
  • Home
  • Trending
  • Texas
  • World
  • Politics
  • Opinion
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Books
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: F.D.A. Clears Covid Drug From Eli Lilly That Shows Promise Against Omicron
Share
The Texas ReporterThe Texas Reporter
Font ResizerAa
Search
  • Home
  • Trending
  • Texas
  • World
  • Politics
  • Opinion
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Books
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© The Texas Reporter. All Rights Reserved.
Politics

F.D.A. Clears Covid Drug From Eli Lilly That Shows Promise Against Omicron

Editorial Board
Editorial Board Published February 11, 2022
Share
F.D.A. Clears Covid Drug From Eli Lilly That Shows Promise Against Omicron
SHARE

With Covid treatments still in short supply in the United States, the Food and Drug Administration on Friday gave emergency authorization to a new monoclonal antibody drug that has been found in the laboratory to be potent against the Omicron variant of the coronavirus.

The Biden administration said it would make the therapy immediately available to states free of charge.

The authorization of the treatment, bebtelovimab, means that the United States now has four drugs available for high-risk Covid patients early in the course of their illness that have been found to neutralize the Omicron variant. While there is a greater menu of Covid pills and treatments now than at any other point in the pandemic, the drugs have been so scarce that doctors have been forced to make painful rationing decisions during the Omicron surge.

The drug that the F.D.A. authorized on Friday is manufactured by Eli Lilly, which said on Thursday that it had signed a contract with the Department of Health and Human Services to provide the government with up to 600,000 courses of the treatment for at least $720 million. The company said it had already manufactured hundreds of thousands of doses and was ready to begin shipments within 24 hours.

The Lilly drug has not been tested in a study that can show whether it can stave off severe disease. The F.D.A. said it should not be a preferred product and instead should be used only when alternative treatments are not “accessible or clinically appropriate.” Federal health officials have given a similar designation to a Covid pill from Merck and the Covid vaccine from Johnson & Johnson.

However, there are data suggesting Eli Lilly’s drug is safe and may reduce the amount of virus that builds up in people who are sick with Covid.

Like other drugs for recently diagnosed Covid patients, Lilly’s new treatment is authorized for people who are vulnerable to becoming seriously ill because they are older or have a medical condition like obesity or diabetes. People as young as 12 can be eligible.

The drug is meant to be given as a quick intravenous injection by a health care provider, typically at a clinic or hospital. It must be administered within seven days of symptoms starting.

Eli Lilly tested the drug in a mid-stage clinical trial before the emergence of the highly transmissible Omicron variant; the trial enrolled Delta-infected patients. Unvaccinated volunteers with an average risk of becoming seriously ill with Covid had their symptoms clear up faster when they were treated with the drug and had a lower level of virus in their bodies after five days compared with those who received a placebo, the F.D.A. said.

The study also enrolled higher-risk people, some of whom were vaccinated, and examined whether the drug was safe for them. Across the company’s safety studies, the drug was found to cause rare instances of relatively mild side effects, including infusion-related reactions, itchiness and a rash.

Updated 

Feb. 11, 2022, 9:24 p.m. ET

Monoclonal antibody drugs are synthetic versions of the antibodies generated naturally when the body fights off the virus. They were widely used during the Delta surge last summer, particularly in red states. But during the ongoing surge, the country’s supply of the drugs has been sharply reduced because two of the three authorized products are ineffective against Omicron.

That left just one such treatment, made by GlaxoSmithKline, available. Biden administration officials have been shipping roughly 50,000 doses a week of the Glaxo treatment to states. The purchase of bebtelovimab will allow them to double the number of people receiving monoclonal antibodies that work against Omicron.

Falling case counts and a gradual increase in the supply of two new treatments meant for the same group of high-risk patients — antiviral pills from Pfizer and Merck — are also helping ease treatment shortages.

The Coronavirus Pandemic: Key Things to Know


Card 1 of 4

Covid boosters. Data released by the Centers for Disease Control and Prevention showed that booster shots against the coronavirus lose much of their potency after about four months, adding to evidence suggesting that some Americans may need a fourth dose.

Vaccines for young children. The Food and Drug Administration said that it would wait for data on the effectiveness of three doses of the Pfizer-BioNTech coronavirus vaccine in children younger than 5 before deciding whether to authorize it for that age group.

Xavier Becerra, the secretary of health and human services, announced the deal with Lilly on Thursday. He said the company would ship the government 300,000 courses in February and another 300,000 in March. The contract includes a future option for 500,000 additional doses.

Before the emergence of Omicron, the country’s three authorized antibody treatments — from Eli Lilly, Regeneron and Glaxo — were found in clinical trials to sharply reduce the risk of being hospitalized or dying from the virus.

But when Omicron was discovered, laboratory studies quickly found that the products from Eli Lilly and Regeneron were not effective against Omicron. Last month, the F.D.A. sharply limited use of the two products, and the federal government stopped shipping them to states.

Eli Lilly had been developing bebtelovimab long before the emergence of Omicron as part of its collaboration with the Vaccine Research Center, an arm of the National Institute of Allergy and Infectious Diseases. It did so out of “fear that there could be a new highly resistant variant,” Dr. Daniel Skovronsky, Eli Lilly’s chief scientific officer, said in an interview.

The company began safety testing of bebtelovimab early last year and then manufactured hundreds of thousands of doses of the drug before knowing whether it would be needed. More recently, the company tested the drug in laboratory experiments that found that it remained highly potent against Omicron.

Dr. Skovronsky said the urgency of the fast-changing pandemic and strong laboratory data justified bringing the drug to market before testing it in patients with Omicron.

“If the national strategy is every time there’s a new variant, we need to do clinical trials for that variant, we’ll never have the drugs in time,” he said. “We’ll always be one variant behind.”

TAGGED:Politics
Share This Article
Twitter Email Copy Link Print
Previous Article Independents defect from Biden, deliver another bad omen for Democrats in November Independents defect from Biden, deliver another bad omen for Democrats in November
Next Article Biden to speak with Putin as U.S. warns Ukraine invasion could be imminent Biden to speak with Putin as U.S. warns Ukraine invasion could be imminent

Editor's Pick

Sizzling Lady Summer time Begins within the Bathe—Right here’s Learn how to Prep Your Pores and skin

Sizzling Lady Summer time Begins within the Bathe—Right here’s Learn how to Prep Your Pores and skin

We might obtain a portion of gross sales if you buy a product by a hyperlink on this article. Most…

By Editorial Board 8 Min Read
Alpine’s Sizzling Hatch EV Has a Constructed-In, ‘Gran Turismo’ Model Driving Teacher

One other win over its Renault 5 sibling is a multi-link rear…

3 Min Read
Louis Vuitton Is Dropping a New Perfume As a result of It’s Sizzling | FashionBeans

We independently consider all beneficial services and products. Any services or products…

2 Min Read

Latest

“A Family’s Fight to Reclaim Their Legacy”

“A Family’s Fight to Reclaim Their Legacy”

Introduction: For generations, the Wright family has worked and lived…

July 9, 2025

AR Global Inc CEO Kason Roberts Donates to Support Kerrville Storm Victims, Mobilizes Team for Restoration Efforts

Kerrville, Texas — In the aftermath…

July 9, 2025

Bitcoin Tops $109,000 After Senate Passes Trump’s ‘Big Beautiful Bill’ – “The Defiant”

The crypto market posted modest good…

July 9, 2025

Two vital hazard alerts within the June employment report – Indignant Bear

Two vital hazard alerts within the…

July 9, 2025

Simone Biles Thirst Traps in Bikini Amidst Boob Job Hypothesis

Studying Time: 3 minutes Simone Biles…

July 9, 2025

You Might Also Like

Trump hasn’t delivered ‘no taxes on tips’ promise—however Democrats ought to
Politics

Trump hasn’t delivered ‘no taxes on tips’ promise—however Democrats ought to

In its explainer on President Donald Trump’s “no taxes on tips” provision in his “One Big, Beautiful Bill,” NPR used…

5 Min Read
Elon Musk’s obnoxious political ambitions are tanking Tesla
Politics

Elon Musk’s obnoxious political ambitions are tanking Tesla

Tesla traders reportedly aren’t thrilled about CEO Elon Musk’s plans to launch a political get together. Based on The Washington…

6 Min Read
Sign is again to hang-out the Trump workforce—this time concentrating on Marco Rubio
Politics

Sign is again to hang-out the Trump workforce—this time concentrating on Marco Rubio

There’s an impersonator of Secretary of State Marco Rubio on the free, and so they’re utilizing synthetic intelligence to focus…

4 Min Read
RFK Jr. is steering public well being companies off a cliff
Politics

RFK Jr. is steering public well being companies off a cliff

It’s tough to maintain monitor of all of the methods through which Well being and Human Providers Secretary Robert F.…

6 Min Read
The Texas Reporter

About Us

Welcome to The Texas Reporter, a newspaper based in Houston, Texas that covers a wide range of topics for our readers. At The Texas Reporter, we are dedicated to providing our readers with the latest news and information from around the world, with a focus on issues that are important to the people of Texas.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact Us

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© The Texas Reporter. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?